Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

 
• By Joseph Haas
  
3d illustration of red blood cells in the artery
Six partner companies hope to derive a plasma-based COVID therapy from donors who survived the virus
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip